Data Information and Disclaimers
The locations displayed above have received an order of Paxlovid or Lagevrio (molnupiravir) in the last two months and/or have reported availability of the oral antiviral medications within the last two weeks. Those sites that have not reported in the last two weeks display a notification with the site details, "Inventory has not been reported in the last 2 weeks. Please contact the provider to make sure the product is available."

All therapeutics identified in the locator must be used in alignment with the terms of the respective product’s EUA. Data displayed on this page is for informational purposes only. The data on this page is for locations with the oral antivirals Pfizer's Paxlovid and Merck's Lagevrio (molnupiravir). Visit COVID-19 Treatments and Therapeutics for more information on all treatment options.

The medication is provided at no cost. Some sites may charge for services not covered by insurance. Some sites may offer telehealth services. This website is intended for informational purposes only and does not serve as an endorsement or recommendation for use of any of the locations listed on the sites.

Clarification for DoD Facilities: Those individuals eligible for care in an MTF include Active Duty Service Members (ADSMs), covered beneficiaries enrolled in TRICARE Prime or Select, including TRICARE Reserve Select (TRS), TRICARE Retired Reserve (TRR) and TRICARE Young Adult (TYA) participants, TRICARE for Life beneficiaries, and individuals otherwise entitled by law to MTF care (e.g., regular retired members and their dependents who are not enrolled in TRICARE but who are otherwise eligible for MTF space-available care, certain foreign military members and their families registered in DEERS, and others).

Locations of COVID-19 Test to Treat sites. Dataset only includes locations for Paxlovid (Antiviral) and Lagevrio (molnupiravir). COVID-19 therapeutics require a prescription to obtain.

Template for requested daily data reports on testing, capacity and utilization, and patient flows to facilitate the public health response to the 2019 Novel Coronavirus (COVID-19).

This time series dataset includes viral COVID-19 laboratory test [Polymerase chain reaction (PCR)] results from over 1,000 U.S. laboratories and testing locations including commercial and reference laboratories, public health laboratories, hospital laboratories, and other testing locations. Data are reported to state and jurisdictional health departments in accordance with applicable state or local law and in accordance with the Coronavirus Aid, Relief, and Economic Security (CARES) Act (CARES Act Section 18115).

Data are provisional and subject to change.

Data presented here is representative of diagnostic specimens being tested - not individual people - and excludes serology tests where possible. Data presented might not represent the most current counts for the most recent 3 days due to the time it takes to report testing information. The data may also not include results from all potential testing sites within the jurisdiction (e.g., non-laboratory or point of care test sites) and therefore reflect the majority, but not all, of COVID-19 testing being conducted in the United States.

Sources: CDC COVID-19 Electronic Laboratory Reporting (CELR), Commercial Laboratories, State Public Health Labs, In-House Hospital Labs

Data for each state is sourced from either data submitted directly by the state health department via COVID-19 electronic laboratory reporting (CELR), or a combination of commercial labs, public health labs, and in-house hospital labs. Data is taken from CELR for states that either submit line level data or submit aggregate counts which do not include serology tests.

More than 450 public health and clinical laboratories located throughout the United States participate in surveillance for severe acute respiratory virus coronavirus type 2 (SARS-CoV-2), the virus that causes COVID-19, through CDC's National Respiratory and Enteric Virus Surveillance System (NREVSS). The dataset contains a weekly summary of aggregate counts of the total SARS-CoV-2 tests and SARS-CoV-2 detections reported to NREVSS since March 14, 2020. These data are reported weekly on a voluntary basis. Clinical laboratories do not report demographic data through NREVSS. Testing practices may vary regionally, and the number of participating laboratories may change from year to year. Results can be changed for up to 2 years after the initial reporting week. However, discrepancies may be noted and updated at the discretion of the data stewards and key stakeholders.

While NREVSS strives to present the most precise estimates of respiratory viral trends with reporting burden minimized for participating laboratories, there are several inherent limitations to this surveillance system.

NREVSS does not collect patient-specific data or demographic information. Multiple samples may be collected from a single patient, so NREVSS results do not necessarily reflect the number of patients tested, nor do they directly reflect hospitalizations or deaths related to COVID-19.

Participating laboratories vary in size, testing capabilities, and areas served. Some institutions may receive and test samples from sites across a given state or even from multiple states. Without direct knowledge of the population base, NREVSS cannot be used to determine the prevalence or incidence of infection.

For more information on NREVSS and COVID-19 surveillance please visit: https://www.cdc.gov/surveillance/nrevss. These data appear starting May 25, 2023 on the CDC COVID Data Tracker at the following URLs: https://covid.cdc.gov/covid-data-tracker/#trends ; https://covid.cdc.gov/covid-data-tracker/#cases.

NREVSS data are reported at the national and HHS regional levels. The ten (10) U.S. Department of HHS regions are defined here: https://www.hhs.gov/about/agencies/iea/regional-offices/index.html.

The data represent SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) results, which include reverse transcriptase-polymerase chain reaction (RT-PCR) tests from a voluntary, sentinel network of participating laboratories in the United States, including clinical, public health and commercial laboratories (https://www.cdc.gov/surveillance/nrevss/labs/index.html).

These data exclude antigen, antibody, and at-home test results.

All data are provisional and subject to change. Reporting is less complete for the past 1 week, and more complete (>90%) for the period 2 weeks earlier.

There are data from all states across the 10 HHS regions. Because the data are from a sentinel network of laboratories, however, results may vary geographically. The data do not include all test results within a jurisdiction and therefore do not reflect all SARS-CoV-2 NAATs administered in the United States.

Percent positivity is one of the surveillance metrics used to monitor COVID-19 transmission over time and by area. Percent positivity is calculated by dividing the number of positive NAATs by the total number of NAATs administered, then multiplying by 100 [(# of positive NAAT tests / total NAAT tests) x 100].

The data represent laboratory tests performed, not individual (deduplicated) results in people. In the table and upon hovering on the map, the total test counts in the data reflect the latest data reported from NREVSS laboratories and may not match the data presented by various jurisdictions.

On May 11, 2023, CDC discontinued utilizing the COVID electronic laboratory reporting (CELR) platform as the primary laboratory source of COVID-19 results. These data are archived at health.data.gov.

For more information about NREVSS, please see: https://www.cdc.gov/surveillance/nrevss/